Arachidonic acid metabolism plays an important role in acute ischemic syndromes affecting
the coronary or cerebrovascular territory, as reflected by biochemical measurements of
eicosanoid biosynthesis and the results of inhibitor trials in these settings. Two
cyclooxygenase (COX)‐isozymes have been characterized, COX‐1 and COX‐2, that differ in
terms of regulatory mechanisms of expression, tissue distribution, substrate specificity,
preferential coupling to upstream and downstream enzymes and susceptibility to inhibition …